Indeed, we observed that CD19-ReTARGTPR efficiently redirected anti-CMVpp65 CTLs to eliminate cancer cells with low levels of CD19, a context in which CD19 CAR T cells and blinatumomab exhibited markedly diminished activity. This evidence concerns the gene CD19 and cancer.